Scully Calls Reimbursement Squeeze-Play On Prices; CMS/FDA MoU Imminent
This article was originally published in The Gray Sheet
Executive Summary
CMS is curbing device prices by setting reimbursement levels for new technology at slightly lower rates than the prices charged by manufacturers, according to Administrator Tom Scully